Human recombinant granulocyte-macrophage colony-stimulating factor in pediatric oncology practice.
This paper reports preliminary experiences with human recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) in children with malignant diseases administered for three indications: (1) chemotherapy-induced neutropenia and sepsis, (2) prolonged neutropenia decreasing dose intensity, and (3) prevention of neutropenia after sublethal doses of chemotherapy. It was concluded that in the daily dose of 5 micrograms/kg subcutaneously, GM-CSF is capable of reducing the duration of chemotherapy-induced neutropenia and may be an effective tool in maintaining dose intensity and achieving dose escalation.
Ferencz
T
T
2nd Department of Pediatrics, Semmelweis Medical School, Budapest, Hungary.
Csaki
C
C
Schuler
D
D
Borsi
J D
JD
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D009369:Neoplasms / Q000628:therapy*; D009503:Neutropenia / Q000517:prevention & control / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor